Sarepta Therapeutics (LTS:0L35) FFO


LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
51 GF Score
Price $16.10
GF Value $128.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0L35
51GF Score
Sarepta Therapeutics Inc LTS:0L35
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $16.10 is trading 87.4% below its estimated GF Value™ of $128.15. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • FFO:
  • GF Value™: $128.15 vs. price of $16.10 (87.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score

Get the complete analysis for LTS:0L35

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.10
Price
$128.15
GF Value